How Often are druggable mutations detectable in Metastatic Castration Resistant Prostate Cancer?

可药性 前列腺癌 医学 突变 癌症研究 基因 癌症 前列腺 淋巴结 前列腺切除术 MLH1 放大器 肿瘤科 多路复用 基因突变 内科学 点突变 细胞 支票2 融合基因
作者
Olivia Steenbock,Constantin Rieger,Julian Heidenreich,Pia Paffenholz,David Pfister,Melanie von Brandenstein,Axel Heidenreich
出处
期刊:Urologia Internationalis [Karger Publishers]
卷期号:: 1-1
标识
DOI:10.1159/uin/aewag003
摘要

OBJECTIVES: To analyze the type and frequency druggable mutations in patients with progressive metastatic castration-resistant prostate cancer (mCRPC). PATIENTS AND METHODS: From 2018 to 2023, 311 patients with mCRPC underwent molecular panel analysis of archived prostatectomy samples (n=96) or CT-guided biopsies of progressive metastases (n=215).Mutation analysis was performed using NGS with an 18 multiplex PCR amplicon (AR, ATM, AURKA/MYC, BRCA1/2, CDK12, CTNNB1, DLL3, ETS family, FOXA1, FOXO1, MED12, PIK3CA, PTEN, RAD51C, TP53, Wnt-Pathway). Since 2023, we applied the TSO500 panel in selected cases. The HRD score was calculated by combining BRCA1 and BRCA2 mutations (Genomic ScarScore GSS) using the HANDLE HRD Focus Panel. The data were evaluated using the following thresholds: tumor cell content ≥ 30%, GScore positive at ≥ 50, HRD positive: GScore at ≥ 50 or BRCA1/2 category 4/5 mutation. MSI-high and mutations of MSH2, MSH6, PMS2, and MLH1 were analysed. The following databases were reviewed to identify druggable mutations: OncoKB, ClinVar, JAX-CKB, COSMIC, and My Cancer Genome. RESULTS: 299/311 (96%) biopsies had sufficient DNA content for NGS. NGS was performed from prostate (31%), lymph node (30%), visceral (15%), and bone (24%) metastases with informative DNA retrival in 95%, 95%, 92%, and 85%, respectively. 157 patients (50.5%) had no or non druggable mutations, while 154 patients (49.5%) exhibited druggable mutations. HRD gene mutations and inactivating p53 mutations were observed in 66 patients (22%). 3 patients had p53 mutations with gain-of-function resulting in ATM inactivation. 50% of HRD gene mutations iwere pathogen and treated with PARPi resulting in a progression-free survival of 3-28 months. Activating AR mutations and inactivating PTEN/activating PIC3Ca mutations were found in 42 (14%) and 24 (8%) patients, respectively. Switch of treatment for AR mutation resulted in PFS of 6-9 months. Mismatch repair deficiency/MSI high mutations were identified in 3 cases who received pembrolizumab with a PFS of 4-8 months. CONCLUSIONS: NGS analysis in mCRPC reveals mutations in two-thirds of patients, of which 41% are already druggable. Only 50% of druggable mutations are based on BRCA1/2 or ATM. NGS analysis should be integrated into the diagnostic armentarium following failure of first-line systemic therapy for mCRPC.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
野生大型皮皮完成签到,获得积分10
刚刚
限时达发布了新的文献求助10
刚刚
科研通AI6.3的应助被corleeang采纳,获得10
刚刚
bkagyin的应助被年轻觅山采纳,获得10
刚刚
六六发布了新的文献求助10
1秒前
星1993发布了新的文献求助10
1秒前
2秒前
2秒前
Present发布了新的文献求助30
3秒前
3秒前
指尖发布了新的文献求助10
3秒前
Lily发布了新的文献求助10
3秒前
科研通AI6.2的应助被什米采纳,获得10
3秒前
深情安青的应助被友好的诗筠采纳,获得10
3秒前
4秒前
4秒前
Cheryl发布了新的文献求助10
5秒前
li完成签到,获得积分10
5秒前
ddddd完成签到,获得积分10
5秒前
5秒前
7秒前
7秒前
春申君发布了新的文献求助10
7秒前
ding的应助被天真的日记本采纳,获得10
8秒前
8秒前
9秒前
七月流火的应助被rapamycin采纳,获得10
9秒前
舒适雪糕完成签到,获得积分10
9秒前
深情安青的应助被cc采纳,获得10
9秒前
9秒前
哎哟可爱完成签到,获得积分10
9秒前
10秒前
bkagyin的应助被大意的面包采纳,获得10
10秒前
沈吃俭用完成签到,获得积分10
10秒前
ayzx完成签到,获得积分10
10秒前
10秒前
做好人难完成签到,获得积分10
10秒前
陈二坎发布了新的文献求助10
10秒前
10秒前
林木木发布了新的文献求助30
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183142
求助须知:如何正确求助?哪些是违规求助? 9572420
关于积分的说明 21825253
捐赠科研通 7779922
什么是DOI,文献DOI怎么找? 3433850
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480124